Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABP-671 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| ABP-671, Cohort 1- | EXPERIMENTAL | ABP-671, Cohort 1 participants received 50 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo). |
| ABP-671, Cohort 2- | EXPERIMENTAL | ABP-671, Cohort 2 participants will receive 0.1 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo). |
| ABP-671, Cohort 3- | EXPERIMENTAL | ABP-671, Cohort 3 participants will receive 0.5 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo). |
| ABP-671, Cohort 4- | EXPERIMENTAL | ABP-671, Cohort 4 participants will receive 1.0 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo). |
| Name | Type | Description |
|---|---|---|
| ABP-671 | DRUG | Drug: ABP-671, single oral dose |
| Placebo | OTHER | Other: Placebo, single oral dose |
Inclusion Criteria 1. Healthy (no clinically significant health concerns), as determined by medical history, physical examination, 12-lead ECG, and vital signs. 2. Participants serum uric acid level at screening ≥ 4.0 mg/dL to ≤ 5.5 mg/dL for males, and ≥ 4.0 mg/dL to ≤ 5.0 mg/dL for females. 3. Pa...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Amgen Inc. | AMGN | 1 | PHASE3 | Pegloticase, Methotrexate |
| Protalix BioTherapeutics, Inc. (DE) | PLX | 1 | PHASE2 | PRX-115, Methotrexate |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | PHASE1 | NNC4004-0002 |
| TJ Biopharma Co., Ltd. | IMAB | 1 | PHASE2 | Plonmarlimab, Compound betamethasone |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE1 | Pegylated Recombinant Candida Utilis Uricase |
ABP-671 is an investigational small molecule being developed for the treatment of gout, a metabolic condition characterized by elevated uric acid levels. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
ABP-671 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The drug is in early-stage clinical development for gout.
ABP-671 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. Its Phase 1 trial has been completed.
ABP-671 has one completed Phase 1 clinical trial, identified as NCT03906006. This study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABP-671 in healthy subjects with gout or hyperuricemia. The trial enrolled 32 participants in the United States.
No alternative names for ABP-671 have been disclosed. It is identified solely by its development code, ABP-671, in clinical trial registries and company communications.